Naproxen — research review 1

...and this brings us to naproxen, a long-acting NSAID commonly used for pain relief. It acts by inhibiting prostaglandins through the COX pathway, reducing inflammation. But what's its relationship with aging and all-cause mortality, especially for chronic pain management?

That's a crucial question. While naproxen effectively manages pain, the evidence suggests a nuanced picture regarding its long-term effects. A study in Osteoarthritis and Cartilage (2021) found that topical NSAIDs had significantly lower risks of all-cause mortality, cardiovascular disease, and gastrointestinal bleeding compared to oral forms. Specifically, topical NSAIDs showed an HR of 0.59 for all-cause mortality compared to oral comparators. This implies that while the pain relief is real, the systemic exposure from oral naproxen carries greater risks.

So, the delivery method matters significantly. And speaking of inflammation, we know it's a key driver of biological aging.

Exactly. Chronic inflammation, often measured by markers like IL-6, is strongly linked to all-cause mortality. Experimental Gerontology (2015) reported that serum IL-6 had the most robust dose-response relationship with all-cause mortality in the oldest old. While naproxen aims to reduce acute inflammation, chronic use of oral forms could potentially contribute to systemic inflammatory processes or other harms that paradoxically impact longevity.

So, while it addresses pain, the long-term impact of oral naproxen on things like biological aging and all-cause mortality isn't fully established as beneficial, and some evidence points to potential harms.

Right. We need more research on the direct epigenetic and biological aging effects of long-term oral NSAID use, especially weighing the benefits of pain relief against these systemic risks. For now, it’s about weighing the evidence carefully with your healthcare provider.